



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On June 4, 2003

TOWNSEND and TOWNSEND and CREW LLP

By: Kathryn A. Deglantos

Attorney Docket No.: 20553C-003410US
Client Ref. No.: FCV-5630

PATENT

17.7.03

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Crystal M. Cunanan et al.

Application No.: 10/004,624

Filed: November 1, 2001

For: METHODS FOR PREPARATION
OF BIOPROSTHETIC TISSUE AND
IMPLANTABLE DEVICES
COMPRISING SUCH BIOPROSTHETIC
TISSUE

Examiner: Winkler, Ulrike

Art Unit: 1648

**RESPONSE TO RESTRICTION
REQUIREMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement mailed February 4, 2003, Applicants elect, with traverse, the claims of Group VIII (Claims 50-60) for prosecution on the merits drawn to a method of eliminating or reducing calcification in a biological material by removing a phospholipid calcium nucleation site contained in the material. Applicants petition to extend the period for response in the above-identified patent application for two months, from March 4, 2003 to June 4, 2003. A Fee Transmittal authorizing the Commissioner to charge the petition fee to our deposit account is attached.

06/09/2003 SDENBOB1 00000102 201430 10004624

01 FC:1253

930.00 CH

Applicants request reconsideration of Groups I and II as independent inventions and Groups VI and VII as independent inventions.

The invention claimed by Applicants in Groups I and II arises out of a common inventive concept or idea. The common, novel concept of this invention is that binding of an infectious agent or unwanted protein can be prevented by removing a binding site contained in the material. Each of the claims of Groups I and II arises out of this common, novel idea.

The invention claimed by Applicants in Groups VI and VII also arises out of a common inventive concept or idea. The common, novel concept of this invention is that infection of a bioprosthetic tissue can be eliminated or reduced by blocking the interaction between a binding site contained in the tissue and an infectious agent. Each of the claims of Groups VI and VII arises out of this common, novel idea.

In addition, Applicants respectfully remind the Examiner that in order to properly restrict the claims, there must be serious burden on the Examiner if the claims are not restricted (see MPEP §803). Because the claims of Groups I and II are closely related by a common inventive concept, the burden on the Examiner to search the claims Groups I and II covering the common inventive concept is minimal. In addition, because the claim of Groups VI and VII are closely related by a common inventive concept, the burden on the Examiner to search claims Groups VI and VII covering the respective common inventive concept is minimal.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Kenneth E. Jenkins, Ph.D.
Reg. No. 51,846

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
KEJ:kej

SF 1458738 v1